Next
Generation Sequencing (NGS) is a powerful, flexible, and
indispensable biological tool that is used in several areas of
biological study. NGS technologies help in generating genome-wide
sequence data in a couple of days. These technologies are highly
parallelized allowing to sequence thousands to millions of molecules
at the same time. The main advantage of these platforms is
determination of the sequenced data from amplified single DNA
fragments, avoiding the need for cloning of DNA fragments.
NGS
has large number of applications, enabling rapid technological
advances across several fields in biological science. The technology
has enabled researchers to gain significant knowledge in public
health studies and epidemiology, to sequence viruses and bacteria and
help detect causes that may contribute to virulence. Furthermore, in
gene expression research, next generation sequencing of RNA replace
microarray analysis, allowing researchers to see RNA expression
sequence. This RNA sequencing can provide information on entire
transcriptome in one analysis, irrespective of any previous knowledge
of genetic sequence.
Free
Request Sample of Report:
https://www.coherentmarketinsights.com/insight/request-sample/158
The
global next generation sequencing market was valued at US$ 5.6
billion in 2017 and is expected to witness a robust CAGR of 18.1%
over the forecast period (2017–2025).
Rising
demand for early detection of cancer and infectious diseases to drive
growth of the NGS market
The
chances of successful treatment increase when cancer and infectious
diseases are detected at the early stage. One of the major factors
that drive growth of the next generation sequencing market is the
rising prevalence of cancer and other infectious diseases. According
to the World Health Organization (WHO), in 2012, new cases of cancer
was around 14 million and the incidence is estimated to increase to
70% by 2030.
Increasing
demand for DNA testing
Demand
for DNA testing is increasing, due to advancements in whole genome
and exome sequencing procedures, faster results and cost effectives
of the process as compared to genotyping based DNA microarray. In
December, 2014, the first commercial sequencer, MinIon, using
Nanopore technology was introduced by Oxford Nanopore Technologies.
The sequencer identifies DNA by measuring the changes in the
electrical conductivity generated DNA strands passed through
biological pore. This technology enabled the detection of outbreaks
such as Zika virus. Furthermore, GenapSys, a U.S.-based developer of
DNA sequencing technologies for applied genomic testing, introduced
GENIUS sequencer, which can sequence DNA anywhere.
Key
players in the next generation sequencing market include Thermo
Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A.,
F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford
Nanopore Technologies, and Beijing Genomics Co. Ltd.
Detailed
Segmentation:
Global
Next Generation Sequencing Market, By Technology:
-
Whole Genome Sequencing
-
Whole Exome Sequencing
-
RNA Sequencing
-
Targeted Re-sequencing
-
Others
Global
Next Generation Sequencing Market, By Application:
-
Drug Discovery
-
Personalized Medicine and Genetic Screening
-
Disease Diagnosis
-
Agriculture and Animal Research
-
Others
Browse
Research Report @
https://www.coherentmarketinsights.com/market-insight/next-generation-sequencing-market-158
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
